within Pharmacolibrary.Drugs.ATC.P;

model P02BX04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.12,
    Cl             = 1.1666666666666666e-05,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0012,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0006666666666666666,
    Tlag           = 1800
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>P02BX04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Triclabendazole is a benzimidazole anthelmintic used primarily for the treatment of fascioliasis (liver fluke infections), caused by Fasciola hepatica and Fasciola gigantica. It acts by disrupting the microtubule function in the parasite. The drug is approved and recommended for use in humans by the World Health Organization and is included among essential medicines.</p><h4>Pharmacokinetics</h4><p>Reported pharmacokinetic parameters in healthy adult volunteers after single oral dose.</p><h4>References</h4><ol><li><p>Martin, P, et al., &amp; Hennessy, D (2009). Efficacy against Fasciola hepatica and the pharmacokinetics of triclabendazole administered by oral and topical routes. <i>Australian veterinary journal</i> 87(5) 200–203. DOI:<a href=&quot;https://doi.org/10.1111/j.1751-0813.2009.00425.x&quot;>10.1111/j.1751-0813.2009.00425.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19382929/&quot;>https://pubmed.ncbi.nlm.nih.gov/19382929</a></p></li><li><p>Mohammed Ali, NA, et al., &amp; Richards, RJ (1986). Pharmacokinetics of triclabendazole alone or in combination with fenbendazole in sheep. <i>Journal of veterinary pharmacology and therapeutics</i> 9(4) 442–445. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2885.1986.tb00067.x&quot;>10.1111/j.1365-2885.1986.tb00067.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3806786/&quot;>https://pubmed.ncbi.nlm.nih.gov/3806786</a></p></li><li><p>Real, D, et al., &amp; Salomon, CJ (2019). Improving the Dissolution of Triclabendazole from Stable Crystalline Solid Dispersions Formulated for Oral Delivery. <i>AAPS PharmSciTech</i> 21(1) 16–None. DOI:<a href=&quot;https://doi.org/10.1208/s12249-019-1551-4&quot;>10.1208/s12249-019-1551-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31807963/&quot;>https://pubmed.ncbi.nlm.nih.gov/31807963</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end P02BX04;
